Table 1 The antibiotic-resistance of the two groups {carbapenem-resistant KP (CR-KP) and carbapenem-susceptible KP}.
|  | CR-KP(n = 71) | CS-KP(n = 71) | OR(95%CI) | p |
|---|---|---|---|---|
ESBL | 5/71 (7%) | 33/71 (46%) | 28.17 (0.03–0.24) | >0.001 |
Piperacillin/sazobactam | 66/69 (96%) | 4/71 (6%) | 113.42 (79.39–1710.42) | >0.001 |
Ampicillin/sulbactam | 63/64 (98%) | 29/64 (45%) | 44.68 (9.93–582.33) | >0.001 |
Cefoperazone/sulbactam | 63/69 (91%) | 3/71 (4%) | 106.49 (57.09–992.20) | >0.001 |
Amoxillin/clavulanic acid | 6/6 (100%) | 5/7 (71%) | 2.03 (0.88–2.24) | 0.16 |
Cefazolin | 67/69 (97%) | 40/70 (57%) | 31.31 (5.69–110.81) | >0.001 |
Ceftazidime | 62/64 (97%) | 16/65 (25%) | 70.44 (20.83–432.76) | >0.001 |
Ceftriaxone | 69/71 (97%) | 35/71 (49%) | 41.54 (8.07–156.02) | >0.001 |
Cefoxitin | 6/6 (100%) | 3/7 (43%) | 4.95 (0.99–5.49) | 0.03 |
Cefepime | 67/71 (94%) | 14/71 (20%) | 80.73 (21.25–218.84) | >0.001 |
Cefotetan | 60/65 (92%) | 1/67 (1.5%) | 109.47 (89.95–6973.50) | >0.001 |
Aztreonam | 65/69 (94%) | 24/71 (34%) | 55.13 (10.35–97.83) | >0.001 |
Tobramycin | 57/69 (83%) | 16/71 (23%) | 50.61 (7.08–37.64) | >0.001 |
Amikacin | 45/70 (64%) | 0/71 (0%) | 67.04 (−) | >0.001 |
Gentamycin | 56/70 (80%) | 13/71 (18%) | 53.68 (7.71–41.32) | >0.001 |
Ciprofloxacin | 53/70 (76%) | 14/71 (20%) | 44.32 (5.70–28.25) | >0.001 |
Levofloxacin | 50/70 (72%) | 10/71 (14%) | 47.42 (6.54–35.54) | >0.001 |
Trimethoprim-sulfamethoxazole | 17/71 (24%) | 25/71 (35%) | 2.16 (0.28–1.20) | 0.14 |
Nitrofurantoin | 68/69 (98%) | 65/71 (92%) | 3.61 (0.74–53.57) | 0.06 |
